Cargando…

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index

BACKGROUND: Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular heterogeneity, the purpose of the present study was to inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Due, Hanne, Brøndum, Rasmus Froberg, Young, Ken H., Bøgsted, Martin, Dybkær, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082970/ https://www.ncbi.nlm.nih.gov/pubmed/32192453 http://dx.doi.org/10.1186/s12885-020-6643-8

Ejemplares similares

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
por: Laursen, Maria Bach, et al.
Publicado: (2019)

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis
por: Jespersen, Ditte Starberg, et al.
Publicado: (2019)

Regression on imperfect class labels derived by unsupervised clustering
por: Brøndum, Rasmus Froberg, et al.
Publicado: (2020)

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission
por: Bødker, Julie Støve, et al.
Publicado: (2017)

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
por: Nesic, Marijana, et al.
Publicado: (2021)

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
por: Karstensen, Kasper Thystrup, et al.
Publicado: (2020)

Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact
por: Schönherz, Anna A., et al.
Publicado: (2020)

Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction
por: Schiøler, Henrik, et al.
Publicado: (2021)

Author Correction: Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction
por: Schiøler, Henrik, et al.
Publicado: (2022)

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
por: Vesteghem, Charles, et al.
Publicado: (2021)

The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma
por: Tanimura, Akira, et al.
Publicado: (2018)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)

Postoperative oscillatory brain activity as an add-on prognostic marker in diffuse glioma
por: Belgers, Vera, et al.
Publicado: (2020)

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
por: Procházka, Vít, et al.
Publicado: (2014)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
por: Lee, Hong Ghi, et al.
Publicado: (2015)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
por: Liu, Ran, et al.
Publicado: (2019)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis
por: Xu, Xin-Tian, et al.
Publicado: (2022)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Screening for Prognostic microRNAs Associated with Treatment Failure in Diffuse Large B Cell Lymphoma
por: Bento, Leyre, et al.
Publicado: (2022)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment
por: Yu, Sisi, et al.
Publicado: (2018)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma
por: Cao, Di, et al.
Publicado: (2021)

P1520: PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601
por: Yoshida, Isao, et al.
Publicado: (2023)

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
por: Li, Lu, et al.
Publicado: (2018)

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
por: Clausen, Michael R, et al.
Publicado: (2019)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_k72cduefbm41tbuki32ov3q8mv